Literature DB >> 31571591

Orphan drug development in China: progress and challenges.

Shuyang Zhang1, Limeng Chen1, Zongjiu Zhang2, Yupei Zhao3.   

Abstract

Mesh：

Year:  2019        PMID： 31571591     DOI： 10.1016/S0140-6736(19)32179-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  National Rare Diseases Registry System (NRDRS): China's first nation-wide rare diseases demographic analyses.

Authors:  Jian Guo; Peng Liu; Limeng Chen; Haohan Lv; Jie Li; Weichao Yu; Kaifeng Xu; Yicheng Zhu; Zhihong Wu; Zhuang Tian; Ye Jin; Rachel Yang; Weihong Gu; Shuyang Zhang
Journal:  Orphanet J Rare Dis       Date:  2021-12-18       Impact factor: 4.123

2.  Evaluating the national system for rare diseases in China from the point of drug access: progress and challenges.

Authors:  Luyao Qiao; Xin Liu; Junmei Shang; Wei Zuo; Tingting Xu; Jinghan Qu; Jiandong Jiang; Bo Zhang; Shuyang Zhang
Journal:  Orphanet J Rare Dis       Date:  2022-09-10       Impact factor: 4.303

3.  Rare disease curative care expenditure-financing scheme-health provider-beneficiary group analysis: an empirical study in Sichuan Province, China.

Authors:  Jia Li; Lian Yang; Yitong Zhang; Hailun Liao; Yuan Ma; Qun Sun
Journal:  Orphanet J Rare Dis       Date:  2022-10-08       Impact factor: 4.303

4.  A case report of neurological adverse events caused by short-term and low-dose treatment of mitotane: The role of therapeutic drug monitoring.

Authors:  Xin Liu; Qiang Fu; Yan Tang; Jian-Hua Deng; Dan Mei; Bo Zhang
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.